PR90552

Stem cell therapy company Amniotics raises SEK 60 million before deduction of transaction costs, in First North IPO to advance lead candidate PulmoStem(TM) into clinic

LUND, Sweden, July 12, 2021 /PRNewswire=KYODO JBN/--

- Novel source of stem cells in full-term amniotic fluid provides basis for

broad pipeline

Amniotics AB (publ) ("Amniotics" or the "Company"), a stem cell therapy company

has raised SEK60 million through its recent listing on Nasdaq First North

Growth Market. The offering was fully subscribed and attracted widespread

interest from Swedish investment companies and family offices as well as the

general public in Sweden, Norway and Finland. The funds will now be deployed to

advance the company's preclinical portfolio of cell therapy candidates based on

mesenchymal stem cells (MSC) from amniotic fluid. Lead candidate PulmoStem(TM),

a first-in-class treatment for pulmonary disease is scheduled to enter the

clinic in Q2, 2022. In addition, Amniotics will expand its stem cell GMP

manufacturing services to research and industry.

Comment from Amniotics' CEO, Kåre Engkilde:

"Cell therapy is attracting record funding worldwide and is a particular

strength in the Nordics. We are extremely happy and satisfied with the strong

support from both existing and new shareholders for this offering. With the

proceeds from the IPO, Amniotics has the financial resources required to move

our lead candidate PulmoStem(TM) into clinical development. It has the

potential to make a real difference to patient's lives. We also have an

exciting number of other maturing candidates across a range of indications in

our preclinical portfolio."

About Amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from

amniotic fluid. The company was born out of discovery of a novel source of stem

cells in full-term amniotic fluid. Based on a decade of research at the

internationally recognized Lund University Stem Cell Centre and the University

Hospital of Lund, the company is pioneering the harvesting and propagation of

tissue specific neonatal quality mesenchymal stem cells (MSC) with unique

properties for applications in regenerative medicine. Amniotics has also an

approved GMP (Good Manufacturing Practice) manufacturing facility to produce

Advanced Therapy Medicinal Products. The GMP facility is operational since 2020

and Amniotics is now moving into clinical trials with the leading drug

candidate, PulmoStem(TM) and is looking to establish strategic partnerships

with researchers and companies interested in developing cell-based therapies

targeting diseases with high unmet needs. Amniotics is listed at Nasdaq First

North Growth Market in Stockholm.

www.amniotics.com

Contact: Kare Engkilde, CEO, Amniotics AB, Phone: +46 (0) 723 27 85 20, Email:

ke@amniotics.com and Johny Humaloja, CFO, Amniotics AB, Phone: +46 (0) 735 06

68 56, Email: jh@amniotics.com

Source: Amniotics AB